ArticleBMJ case reports2026
Glioma-associated oncogene homolog 1-altered mesenchymal tumour of the upper oesophageal sphincter.
Article in BMJ case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioma-associated oncogene homologue 1-altered mesenchymal tumours (GLI1-AMT) are rare, recently characterised soft tissue neoplasms driven by GLI1 fusions or amplifications. They predominantly arise in the head and neck, though their full clinicopathological presentation remains variable.A female in her 30s with a year-long history of progressive dysphagia was found to have a GLI1-AMT of the upper oesophageal sphincter, the first known case at this site. She underwent laser excision of the mass with adjuvant radiotherapy with no disease recurrence to date.Literature review identified 42 additional cases in the head and neck, most commonly affecting the tongue. Genetic alterations include GLI1 amplifications, frequently co-amplified with CDK4 and MDM2, and fusions, typically with ACTB, PTCH1 or MALAT1. Immunohistochemical staining patterns are inconsistent, though CD56, S100 and MDM2 are frequently positive.Classification of GLI1-AMT has evolved over recent years, and research is needed to refine diagnostic criteria and elucidate the behaviour of this spectrum of neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.